SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-033284
Filing Date
2022-06-16
Accepted
2022-06-16 14:25:01
Documents
38
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q1221_rasnatherap.htm   iXBRL 10-Q 331209
2 CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNT f10q1221ex31-1_rasnatherap.htm EX-31.1 10123
3 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PUR f10q1221ex32-1_rasnatherap.htm EX-32.1 3545
  Complete submission text file 0001213900-22-033284.txt   2024071

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE rasp-20211231.xsd EX-101.SCH 26218
5 XBRL CALCULATION FILE rasp-20211231_cal.xml EX-101.CAL 19042
6 XBRL DEFINITION FILE rasp-20211231_def.xml EX-101.DEF 103519
7 XBRL LABEL FILE rasp-20211231_lab.xml EX-101.LAB 223336
8 XBRL PRESENTATION FILE rasp-20211231_pre.xml EX-101.PRE 108958
32 EXTRACTED XBRL INSTANCE DOCUMENT f10q1221_rasnatherap_htm.xml XML 166977
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 221020193
SIC: 2834 Pharmaceutical Preparations